Loews Corp’s AbbVie ABBV Stock Holding History

Loews Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-80,000	Closed	-$12.9M	–	28
2022 Q4	$12.9M	Buy	80,000 +10,000	+14%	+$1.53M	0.12%	10
2022 Q3	$9.39M	Sell	70,000 -10,000	-13%	-$1.43M	0.1%	17
2022 Q2	$12.3M	Hold	80,000	–	–	0.11%	17
2022 Q1	$13M	Sell	80,000 -90,000	-53%	-$13.1M	0.11%	15
2021 Q4	$23M	Sell	170,000 -30,000	-15%	-$3.54M	0.2%	7
2021 Q3	$21.6M	Buy	200,000 +40,000	+25%	+$4.57M	0.2%	6
2021 Q2	$18M	Sell	160,000 -20,000	-11%	-$2.25M	0.15%	13
2021 Q1	$19.5M	Sell	180,000 -15,000	-8%	-$1.6M	0.17%	10
2020 Q4	$20.9M	Buy	195,000 +70,000	+56%	+$6.73M	0.21%	4
2020 Q3	$10.9M	Sell	125,000 -10,000	-7%	-$941K	0.14%	19
2020 Q2	$13.3M	Sell	135,000 -15,000	-10%	-$1.32M	0.16%	14
2020 Q1	$11.4M	Buy	+150,000	New	+$12.8M	0.14%	15

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Loews Corp's ABBV Position: Q1 2023 in Review

Loews Corp sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 80,000 shares — an estimated $12.9M sold.

Loews Corp first reported a position in ABBV in Q1 2020 and held it in 12 quarters. The position peaked at $23M in Q4 2021. 3,141 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Loews Corp reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Loews Corp sold 80,000 AbbVie shares in Q1 2023, an estimated $12.9M.
Loews Corp first reported a position in AbbVie in Q1 2020 and held it in 12 quarters.
Loews Corp's AbbVie position peaked at $23M in Q4 2021.
3,141 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Loews Corp's 13F filing for Q1 2023, filed 11 May 2023.